Marco V Perez, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Perez’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A86952 · Current
Licensed to practise in California · since 2004 · expires 2028-04-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$56,205
Medicare paid this office $56,205 for 583 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $5,428 | $115 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 60 | $4,288 | $32 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 52 | $2,881 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,832 | $71 |
| New patient visit (60+ min) | 14 | $2,728 | $195 |
See all 9 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $5,428 | $115 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 60 | $4,288 | $32 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 52 | $2,881 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,832 | $71 |
| New patient visit (60+ min) | 14 | $2,728 | $195 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 307 | $2,462 | $7 |
| Long return visit (40+ min) | 11 | $1,900 | $173 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 59 | $1,414 | $22 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 13 | $259 | $20 |
Procedures Medicare counted
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
583 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 16% · Women 48% · Also on Medicaid 26% · Health risk score 2.13. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Atrial fibrillation 54% · Coronary heart disease 48% · Heart failure 48% · Chronic kidney disease 43% · Diabetes 33% · Depression 26% · Cancer 22% · Dementia 21% · Stroke 19% · COPD 18%.
The office billed $410,586, Medicare allowed $71,195 and paid $56,205; for 968 services of 50 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 583 | 968 | 75 | 2.13 | $410,586 | $56,205 |
| 2023 | 349 | 623 | 73 | 1.99 | $283,477 | $39,322 |
| 2022 | 1,114 | 1,562 | 74 | 2.15 | $389,247 | $57,221 |
| 2021 | 610 | 910 | 74 | 2.15 | $290,076 | $43,594 |
| 2020 | 396 | 641 | 73 | 2.17 | $246,308 | $37,542 |
| 2019 | 480 | 753 | 74 | 2.16 | $237,220 | $42,411 |
| 2018 | 286 | 535 | 72 | 2.31 | $231,762 | $44,297 |
| 2017 | 302 | 639 | 73 | 2.03 | $296,894 | $55,917 |
| 2016 | 274 | 478 | 71 | 1.92 | $204,705 | $39,366 |
| 2015 | 87 | 202 | 72 | 1.79 | $151,816 | $29,064 |
| 2014 | 169 | 318 | 75 | 2.15 | $196,004 | $38,282 |
| 2013 | 114 | 235 | 73 | 2.09 | $147,935 | $29,169 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 51 | $3,270 | $31 |
| Long return visit (40+ min) | 23 | $3,074 | $123 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,511 | $120 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 46 | $2,340 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,459 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 142 | $1,197 | $7 |
| Programming of dual lead implantable defibrillator system | 13 | $654 | $44 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 26 | $519 | $20 |
| Programming of dual lead pacemaker system | 12 | $451 | $35 |
2022: 10 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 867 | $7,795 | $7 |
| Long return visit (40+ min) | 29 | $4,098 | $124 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,800 | $123 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 48 | $3,067 | $34 |
| New patient visit (60+ min) | 15 | $2,564 | $171 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 38 | $1,891 | $28 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 65 | $1,738 | $24 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,362 | $65 |
| Programming of dual lead implantable defibrillator system | 16 | $1,004 | $53 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 13 | $282 | $22 |
2021: 8 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 420 | $3,623 | $8 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $3,105 | $124 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 45 | $2,909 | $33 |
| Long return visit (40+ min) | 16 | $2,496 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,461 | $66 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 55 | $1,338 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 24 | $1,334 | $27 |
| Return visit (30+ min) | 14 | $1,155 | $82 |
2020: 9 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,980 | $119 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 43 | $2,847 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,855 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 201 | $1,793 | $8 |
| Long return visit (40+ min) | 17 | $1,777 | $105 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 51 | $1,250 | $24 |
| Return visit (30+ min) | 17 | $1,033 | $57 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 21 | $963 | $27 |
| Programming of dual lead pacemaker system | 11 | $404 | $34 |
2019: 12 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $4,084 | $124 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 40 | $2,675 | $39 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 299 | $2,560 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,046 | $66 |
| Return visit (30+ min) | 22 | $1,787 | $66 |
| New patient visit (60+ min) | 12 | $1,654 | $138 |
| Long return visit (40+ min) | 16 | $1,615 | $101 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 51 | $1,251 | $25 |
| Programming of dual lead implantable defibrillator system | 14 | $1,126 | $54 |
| Programming of multiple lead implantable defibrillator system | 11 | $818 | $55 |
| Programming of dual lead pacemaker system | 17 | $736 | $33 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 12 | $476 | $28 |
2018: 10 services
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 27 | $2,371 | $49 |
| New patient visit (60+ min) | 13 | $1,957 | $151 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,955 | $122 |
| Long return visit (40+ min) | 20 | $1,925 | $96 |
| Return visit (30+ min) | 27 | $1,816 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,700 | $65 |
| Programming of dual lead implantable defibrillator system | 17 | $1,267 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 127 | $991 | $7 |
| Programming of dual lead pacemaker system | 18 | $944 | $35 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 26 | $662 | $25 |
2017: 13 services
| Insertion of implantable defibrillator system | 12 | $9,704 | $809 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 15 | $6,817 | $454 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,417 | $122 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 26 | $3,069 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,721 | $65 |
| Return visit (30+ min) | 34 | $2,718 | $66 |
| Long return visit (40+ min) | 16 | $1,793 | $100 |
| Programming of dual lead implantable defibrillator system | 20 | $1,605 | $49 |
| New patient visit (60+ min) | 11 | $1,510 | $137 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 146 | $1,298 | $8 |
| Programming of dual lead pacemaker system | 17 | $942 | $34 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 19 | $539 | $24 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $153 | $11 |
2016: 7 services
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 20 | $2,359 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,701 | $121 |
| Return visit (30+ min) | 20 | $1,611 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 154 | $1,374 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,350 | $64 |
| Programming of dual lead implantable defibrillator system | 11 | $648 | $50 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 15 | $361 | $24 |
2015: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,604 | $64 |
| Return visit (30+ min) | 19 | $1,413 | $57 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,066 | $89 |
2014: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,834 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,589 | $113 |
| Return visit (30+ min) | 13 | $1,439 | $96 |
| New patient visit (30+ min) | 14 | $1,143 | $82 |
| Return visit (30+ min) | 11 | $979 | $70 |
| Programming of dual lead pacemaker system | 20 | $834 | $33 |
| Programming of dual lead implantable defibrillator system | 16 | $781 | $46 |
2013: 5 services
| Return visit (30+ min) | 20 | $2,799 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,068 | $61 |
| New patient visit (30+ min) | 17 | $1,557 | $92 |
| Return visit (30+ min) | 12 | $960 | $64 |
| Programming of dual lead pacemaker system | 11 | $396 | $33 |
Medicaid work
$2,657 in 2024
Medicaid paid $2,657 for 263 billed services this clinician did in 2024, up to 79 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 251 | $2,033 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 12 | $625 |
| 2024 | 263 | 2 | 79 | $2,657 |
| 2023 | 104 | 1 | 99 | $889 |
| 2022 | 874 | 3 | 250 | $8,644 |
| 2021 | 392 | 1 | 92 | $4,069 |
| 2020 | 197 | 1 | 111 | $2,239 |
| 2019 | 174 | 1 | 70 | $1,660 |
| 2018 | 71 | 1 | 62 | $694 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 104 | $889 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 847 | $7,608 |
| Long return visit (40+ min) | 12 | $799 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 15 | $237 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 392 | $4,069 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 197 | $2,239 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 174 | $1,660 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 71 | $694 |
Drugs they prescribed that Part D paid
$131,278
Pharmacies billed $131,278 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 243) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
151 generic and 92 brand-name prescriptions · $131,278 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 62 | $84,112 | $1,357 |
| Xarelto | 29 | $37,785 | $1,303 |
| Dofetilide | 26 | $6,524 | $251 |
| Nadolol | 13 | $968 | $74 |
| Sotalol | 44 | $695 | $16 |
See all 7 drugs
| Eliquis | 62 | $84,112 | $1,357 |
| Xarelto | 29 | $37,785 | $1,303 |
| Dofetilide | 26 | $6,524 | $251 |
| Nadolol | 13 | $968 | $74 |
| Sotalol | 44 | $695 | $16 |
| Metoprolol | 21 | $293 | $14 |
| Flecainide Acetate | 13 | $229 | $18 |
Year by year
| 2024 | 243 | 54 | 0% (0) | 38% | $131,278 |
| 2023 | 350 | 62 | 0% (0) | 42% | $205,601 |
| 2022 | 379 | 61 | 0% (0) | 36% | $180,121 |
| 2021 | 266 | 49 | 0% (0) | 39% | $124,923 |
| 2020 | 184 | 40 | 0% (0) | 43% | $81,830 |
| 2019 | 152 | 38 | None | 32% | $55,039 |
| 2018 | 136 | 28 | 0% (0) | 28% | $33,262 |
| 2017 | 191 | 32 | 0% (0) | 33% | $40,267 |
| 2016 | 155 | 25 | 0% (0) | 28% | $36,299 |
| 2015 | 107 | 20 | None | 18% | $12,701 |
| 2014 | 69 | 22 | None | 17% | $8,162 |
| 2013 | 46 | None | 0% (0) | None | $1,787 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Eliquis | 86 | $111,431 | $1,296 |
| Xarelto | 49 | $66,959 | $1,367 |
| Dofetilide | 26 | $10,727 | $413 |
| Multaq | 11 | $10,346 | $941 |
| Nadolol | 24 | $1,601 | $67 |
| Sotalol | 47 | $1,409 | $30 |
| Metoprolol | 26 | $853 | $33 |
| Flecainide Acetate | 33 | $743 | $23 |
2022: 9 drugs
| Eliquis | 77 | $95,256 | $1,237 |
| Xarelto | 51 | $54,311 | $1,065 |
| Dofetilide | 36 | $13,150 | $365 |
| Nadolol | 52 | $1,514 | $29 |
| Sotalol | 30 | $847 | $28 |
| Amiodarone | 15 | $653 | $44 |
| Metoprolol | 35 | $611 | $17 |
| Sotalol Af | 13 | $481 | $37 |
| Flecainide Acetate | 31 | $384 | $12 |
2021: 7 drugs
| Eliquis | 72 | $72,784 | $1,011 |
| Xarelto | 30 | $30,392 | $1,013 |
| Dofetilide | 26 | $12,181 | $468 |
| Nadolol | 17 | $1,293 | $76 |
| Sotalol | 36 | $988 | $27 |
| Amiodarone | 28 | $981 | $35 |
| Metoprolol | 25 | $476 | $19 |
2020: 6 drugs
| Eliquis | 53 | $47,274 | $892 |
| Xarelto | 17 | $19,188 | $1,129 |
| Dofetilide | 11 | $4,961 | $451 |
| Metoprolol | 15 | $591 | $39 |
| Sotalol | 28 | $542 | $19 |
| Diltiazem 24hr Er (Cd) | 12 | $326 | $27 |
2019: 5 drugs
| Xarelto | 33 | $27,813 | $843 |
| Dofetilide | 14 | $6,929 | $495 |
| Sotalol | 23 | $1,128 | $49 |
| Metoprolol | 15 | $722 | $48 |
| Sotalol Af | 14 | $188 | $13 |
2018: 4 drugs
| Xarelto | 21 | $9,892 | $471 |
| Nadolol | 15 | $1,664 | $111 |
| Sotalol | 20 | $536 | $27 |
| Metoprolol | 17 | $533 | $31 |
2017: 6 drugs
| Multaq | 17 | $12,747 | $750 |
| Xarelto | 19 | $7,347 | $387 |
| Dofetilide | 11 | $3,738 | $340 |
| Nadolol | 28 | $3,146 | $112 |
| Sotalol | 29 | $650 | $22 |
| Metoprolol | 30 | $548 | $18 |
2016: 4 drugs
| Multaq | 23 | $17,313 | $753 |
| Nadolol | 27 | $2,695 | $100 |
| Metoprolol | 34 | $1,100 | $32 |
| Metoprolol | 15 | $137 | $9 |
2015: 3 drugs
| Nadolol | 25 | $2,061 | $82 |
| Metoprolol | 19 | $638 | $34 |
| Metoprolol | 14 | $24 | $2 |
2013: 1 drug
| Carvedilol | 12 | $79 | $7 |
Money from drug and device companies
$75,601 in 2025
| 2025 | 4 | 54 | $59,521 | $75,601 |
| 2024 | 2 | 44 | $36,875 | $42,974 |
| 2023 | 3 | 40 | $32,580 | $37,034 |
| 2022 | 3 | 37 | $27,363 | $32,649 |
| 2021 | 2 | 12 | $8,000 | $8,423 |
| 2020 | 2 | 49 | $5,900 | $5,900 |
| 2019 | 1 | 9 | None | $1,154 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Emblem Mri S-Icd | $54,426 | 39 payments
|
| Biotronik | Acticor 7 Vr-T Dx | $19,896 | 13 payments
|
| Janssen Research & Development | None | $1,240 | 1 payment
|
| Medtronic | Azure Xt Dr Mri Surescan | $39 | 1 payment
|
See all 54 published payments
| Biotronik | Consulting · 2025-12-23 | None | $2,700 |
| Biotronik | Paid to speak or teach · 2025-12-23 | None | $3,750 |
| Biotronik | Travel · 2025-12-23 | None | $34 |
| Biotronik | Meals · 2025-12-23 | None | $61 |
| Biotronik | Travel · 2025-12-23 | None | $320 |
| Boston Scientific | Paid to speak or teach · 2025-12-18 | General - Therapies | $5,000 |
| Boston Scientific | Paid to speak or teach · 2025-12-18 | General - Therapies | $625 |
| Boston Scientific | Meals · 2025-12-18 | General - Therapies | $88 |
| Biotronik | Travel · 2025-12-08 | None | $9,028 |
| Janssen Research & Development | Consulting · 2025-10-27 | None | $1,240 |
| Boston Scientific | Consulting · 2025-10-16 | General - Therapies | $5,000 |
| Boston Scientific | Meals · 2025-10-16 | General - Therapies | $149 |
| Boston Scientific | Travel · 2025-10-16 | General - Therapies | $199 |
| Boston Scientific | Consulting · 2025-10-16 | General - Therapies | $5,781 |
| Medtronic | Meals · 2025-10-04 | Azure Xt Dr Mri Surescan | $39 |
| Boston Scientific | Paid to speak or teach · 2025-09-04 | Emblem Mri S-Icd | $625 |
| Boston Scientific | Travel · 2025-09-04 | Emblem Mri S-Icd | $296 |
| Boston Scientific | Paid to speak or teach · 2025-09-04 | Emblem Mri S-Icd | $10,000 |
| Biotronik | Meals · 2025-08-28 | Acticor 7 Vr-T Dx | $89 |
| Biotronik | Consulting · 2025-08-20 | None | $2,925 |
| Boston Scientific | Paid to speak or teach · 2025-07-03 | Clinical Trial Product | $625 |
| Boston Scientific | Paid to speak or teach · 2025-07-03 | Clinical Trial Product | $3,750 |
| Boston Scientific | Meals · 2025-07-03 | Clinical Trial Product | $41 |
| Boston Scientific | Travel · 2025-07-03 | Clinical Trial Product | $293 |
| Boston Scientific | Meals · 2025-06-21 | General - Therapies | $471 |
| Boston Scientific | Travel · 2025-06-20 | General - Therapies | $639 |
| Boston Scientific | Travel · 2025-06-20 | General - Therapies | $352 |
| Boston Scientific | Meals · 2025-06-13 | Emblem Mri S-Icd | $66 |
| Boston Scientific | Travel · 2025-06-13 | Emblem Mri S-Icd | $222 |
| Boston Scientific | Travel · 2025-06-12 | Emblem Mri S-Icd | $263 |
| Boston Scientific | Travel · 2025-06-12 | Emblem Mri S-Icd | $178 |
| Biotronik | Meals · 2025-05-22 | None | $42 |
| Biotronik | Meals · 2025-05-17 | None | $8 |
| Biotronik | Travel · 2025-05-16 | None | $342 |
| Biotronik | Travel · 2025-05-05 | None | $309 |
| Boston Scientific | Travel · 2025-04-24 | Emblem Mri S-Icd | $200 |
| Boston Scientific | Paid to speak or teach · 2025-04-24 | Emblem Mri S-Icd | $625 |
| Boston Scientific | Paid to speak or teach · 2025-04-24 | Emblem Mri S-Icd | $6,250 |
| Biotronik | Travel · 2025-04-21 | None | $288 |
| Boston Scientific | Paid to speak or teach · 2025-04-17 | Emblem Mri S-Icd | $10,000 |
| Boston Scientific | Paid to speak or teach · 2025-04-17 | Emblem Mri S-Icd | $625 |
| Boston Scientific | Meals · 2025-04-17 | Emblem Mri S-Icd | $56 |
| Boston Scientific | Travel · 2025-04-17 | Emblem Mri S-Icd | $222 |
| Boston Scientific | Meals · 2025-04-05 | Emblem Mri S-Icd | $53 |
| Boston Scientific | Travel · 2025-04-05 | Emblem Mri S-Icd | $59 |
| Boston Scientific | Travel · 2025-04-05 | Emblem Mri S-Icd | $97 |
| Boston Scientific | Travel · 2025-04-04 | Emblem Mri S-Icd | $196 |
| Boston Scientific | Travel · 2025-04-04 | Emblem Mri S-Icd | $129 |
| Boston Scientific | Meals · 2025-03-16 | Farapulse | $14 |
| Boston Scientific | Travel · 2025-03-16 | Farapulse | $96 |
| Boston Scientific | Travel · 2025-03-16 | Farapulse | $379 |
| Boston Scientific | Meals · 2025-03-15 | Farapulse | $180 |
| Boston Scientific | Travel · 2025-03-15 | Farapulse | $327 |
| Boston Scientific | Travel · 2025-03-15 | Farapulse | $256 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $42,974
| Boston Scientific | Emblem Mri S-Icd | $41,466 | 35 payments
|
| Medtronic | Evera Mri Xt Dr Surescan | $1,508 | 9 payments
|
2023: $37,034
| Boston Scientific | S-Icd System Magnet | $32,152 | 37 payments
|
| Janssen Research & Development | None | $3,308 | 2 payments
|
| Shionogi | Fetroja | $1,575 | 1 payment
|
2022: $32,649
| Boston Scientific | S-Icd System Magnet | $23,622 | 29 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $8,883 | 5 payments
|
| Biotronik | Biomonitor | $144 | 3 payments
|
2021: $8,423
| Boston Scientific | Emblem S Icd Electrode Delivery System | $5,300 | 2 payments
|
| Biotronik | Edora | $3,123 | 10 payments
|
2020: $5,900
| Boston Scientific | Emblem | $4,900 | 2 payments
|
| AltaThera Pharmaceuticals | Sotalol Hydrochloride | $1,000 | 1 payment
|
2019: $1,154
| Medtronic Vascular | Micra | $1,154 | 9 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study To Evaluate the Efficacy and Safety of Milvexian, An Oral Factor Xia Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation · 2024 | Their institution | $1,394,827 |
| Janssen Research & Development, LLC · A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study To Evaluate the Efficacy and Safety of Milvexian, An Oral Factor Xia Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation · 2025 | Their institution | $498,752 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1740296607
- Licence
- CA A86952California A86952: Current · expires 2028-04-30
- Trained
- Harvard Medical School, 2001
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-31
- NPI last updated
- 2024-04-24
- NPI record certified
- 2024-04-24
This is when the NPI record was last certified, not a medical board exam.